|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Postgraduate Institute of Medical Education and Research |
|---|---|
| Information provided by: | Postgraduate Institute of Medical Education and Research |
| ClinicalTrials.gov Identifier: | NCT00375375 |
Purpose
Minimal hepatic encephalopathy (MHE) has a negative effect on patients’ daily functioning. No study has so far investigated the effect of treatment related improvement in cognitive functions on health related quality-of-life (HRQOL). This study was carried out to determine the influence of treatment on psychomotor performance and on HRQOL in patients with MHE.
The mean number of abnormal NP tests decreased significantly in patients in treated group compared with patients in untreated group MANOVA for time and treatment, P =.001). Mean total SIP score improved among patients in the treated group after 3 months compared with patients in untreated group after 3 months (MANOVA for time and treatment, P=.002). Improvement in HRQOL was related to the improvement in psychometry. In conclusion, treatment with lactulose improves both cognitive functions and HRQOL in cirrhotic patients with MHE.
| Condition | Intervention | Phase |
|---|---|---|
|
Minimal Hepatic Encephalopathy Hepatic Encephalopathy |
Drug: Lactulose |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Estimated Enrollment: | 80 |
| Study Start Date: | January 2004 |
| Estimated Study Completion Date: | December 2004 |
The study has been published in March 2007 in Hepatology
Lactulose Improves Cognitive Functions and Health-Related Quality of Life in Patients with Cirrhosis WhoHave Minimal Hepatic Encephalopathy.Srinivasa Prasad, Radha K. Dhiman, Ajay Duseja, Yogesh K. Chawla, Arpita Sharma, and Ritesh Agarwal. (HEPATOLOGY 2007;45:549-559.)
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| India | |
| Postgraduate Institute of Medical Education and Research | |
| Chandigarh, UT, India, 160012 | |
| Principal Investigator: | Radha K Dhiman, MD,DM, FACG | Postgraduate Institute of Medical Education and Research, Chandigarh-160012, India |
More Information
| ClinicalTrials.gov Identifier: | NCT00375375 History of Changes |
| Other Study ID Numbers: | Minimal hepatic encephalopathy |
| Study First Received: | September 12, 2006 |
| Last Updated: | March 1, 2007 |
| Health Authority: | India: Institutional Review Board |
|
Minimal hepatic encephalopathy Hepatic encephalopathy Subclinical hepatic encephalopathy Health related quality of life |
|
Hepatic Encephalopathy Brain Damage, Chronic Delirium Encephalitis Neurotoxicity Syndromes Liver Failure Hepatic Insufficiency Liver Diseases Digestive System Diseases Brain Diseases, Metabolic Brain Diseases Central Nervous System Diseases Nervous System Diseases Metabolic Diseases Confusion |
Neurobehavioral Manifestations Neurologic Manifestations Signs and Symptoms Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Central Nervous System Viral Diseases Virus Diseases Central Nervous System Infections Poisoning Substance-Related Disorders Lactulose Gastrointestinal Agents Therapeutic Uses Pharmacologic Actions |